New Protein-Based MRI Contrast Agent Enhances Early Detection of Lung Cancer
Researchers have developed a new class of protein-based MRI contrast agent designed to detect invasive lung cancer and metastatic disease at earlier stages than conventional imaging techniques. The findings, published in the journal Science Advances, reveal a precision MRI method capable of identifying tumors and metastases as small as 1 millimeter. Jenny J. Yang, a professor emerita of biochemistry and biophysical chemistry at Georgia State University, emphasized the significance of this advancement, stating, "This is a game changer for cancer diagnosis and precision medicine." Lung cancer is often diagnosed only after it has metastasized, limiting treatment options. The new technology can detect tiny tumors and hidden metastases without exposing patients to harmful radiation. Additionally, it provides insights into the aggressiveness of the cancer and its likelihood of spreading, which could reduce the need for invasive biopsies. The research details a protein-based MRI contrast agent known as hProCA32.Collagen, which targets collagen type I, a structural protein that is present at elevated levels in aggressive lung tumors and metastatic lesions. In preclinical studies, this technology enabled the detection and quantification of small lung tumors and metastases in various organs, including the lungs, adrenal glands, and kidneys, while mapping biological features associated with tumor invasion and progression. This approach is similar to a previously reported imaging agent developed by Yang's team that targeted the cancer biomarker CXCR4. The hProCA32.collagen agent focuses on abnormal collagen development within the tumor microenvironment, representing a new generation of molecular imaging technology aimed at enhancing imaging capabilities and improving the detection of cancerous cells at earlier stages. The research findings indicate that this method is particularly effective in aggressive lung adenocarcinomas linked to specific mutations that often resist current therapies and are prone to spreading to multiple organs. The study was a collaborative effort involving researchers from Georgia State University, Emory University, The University of Alabama at Birmingham, and other partner institutions. Yang's team at Georgia State, including co-first authors Dongjun "Darren" Li and Oluwabukola "Sophia" Bamishaye, led the development of the collagen-targeted contrast agent and the precision MRI methodology, with imaging studies conducted at Georgia State's Advanced Translational Imaging Facility. Researchers at Emory University, including co-corresponding author Wei Zhou of the Winship Cancer Institute, contributed cancer models and expertise in cancer biology and translational research, while collaborators at UAB provided imaging physics expertise and additional imaging analysis. The study was jointly led by Yang and Zhou. By combining innovative imaging technology with sophisticated cancer metastasis models, the researchers were able to visualize invasive lung cancer and its spread to other organs at much earlier stages than previously possible. The findings may have significant implications for personalized cancer treatment, as they enable physicians to visualize collagen remodeling throughout primary and metastatic tumors. This technology may eventually assist in identifying high-risk patients, guiding treatment selection, and monitoring responses to therapy over time. Yang remarked, "This is a game changer for cancer diagnosis and precision medicine. For the first time, we've shown that precision MRI can detect tiny tumors and whole body metastases without using harmful radiation while also providing important clues about how aggressively a cancer may behave." InLighta Biosciences, a biotechnology company founded by Yang, is helping advance the technology toward clinical use by licensing related intellectual property from Georgia State. Supported in part by the NIH and Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) funding, the company is working to move next-generation protein-based diagnostic and therapeutic agents toward clinical development. Researchers are also working towards an investigational new drug (IND) application with the U.S. Food and Drug Administration to initiate clinical testing of this technology.




